A phase I dose-finding trial of recombinant interleukin-21 and rituximab in relapsed and refractory low grade B-cell lymphoproliferative disorders

Clinical Cancer Research

Volumn 18, Issue 20, 2012, Pages 5752-5760

  Timmerman, John M ^a   Byrd, John C ^b   Andorsky, David J ^a   Yamada, Reiko E ^a   Kramer, Janet ^c   Muthusamy, Natarajan ^b   Hunder, Naomi ^c   Pagel, John M ^d  

^a UCLA MEDICAL CENTER   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c ZYMOGENETICS INC   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT CYTOKINE; RECOMBINANT INTERLEUKIN 21; RITUXIMAB; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; B CELL LYMPHOMA; CANCER REGRESSION; CHILL; CLINICAL ARTICLE; CONSTIPATION; COUGHING; DECREASED APPETITE; DIARRHEA; DIZZINESS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; HEADACHE; HUMAN; HUMAN CELL; HYPOALBUMINEMIA; HYPOPHOSPHATEMIA; HYPOTENSION; INSOMNIA; LEG EDEMA; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; MUSCLE SPASM; NAUSEA; NEUROPATHY; NEUTROPENIA; NIGHT SWEAT; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PAIN; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOXICITY; FEMALE; HUMANS; INTERLEUKINS; LYMPHOMA, B-CELL; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM GRADING; RECOMBINANT PROTEINS;

EID: 84867524002     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-0456     Document Type: Article

References (44)

1. Keating GM. Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma. Drugs 2010;70:1445-76.
2. Jaglowski SM, Byrd JC. Rituximab in chronic lymphocytic leukemia. Semin Hematol 2010;47:156-69.
3. Sousou T, Friedberg J. Rituximab in indolent lymphomas. Semin Hematol 2010;47:133-42.
4. Vidal L, Gafter-Gvili A, Leibovici L, Dreyling M, Ghielmini M, Hsu Schmitz SF, et al. Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials. J Natl Cancer Inst 2009;101:248-55.
5. Taylor RP, Lindorfer MA. Antigenic modulation and rituximab resistance. Semin Hematol 2010;47:124-32.
6. Weiner GJ. Rituximab: mechanism of action. Semin Hematol 2010;47: 115-23.
7. Byrd JC, Kitada S, Flinn IW, Aron JL, Pearson M, Lucas D, et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood 2002;99:1038-43. (Pubitemid 34525569)
8. Jaglowski SM, Alinari L, Lapalombella R, Muthusamy N, Byrd JC. The clinical application of monoclonal antibodies in chronic lymphocytic leukemia. Blood 2010;116:3705-14.
9. Spolski R, Leonard WJ. Interleukin-21: basic biology and implications for cancer and autoimmunity. Annu Rev Immunol 2008;26:57-79. (Pubitemid 351600371)
10. Davis ID, Skak K, Smyth MJ, Kristjansen PE, Miller DM, Sivakumar PV. Interleukin-21 signaling: functions in cancer and autoimmunity. Clin Cancer Res 2007;13:6926-32. (Pubitemid 350276871)
11. Skak K, Kragh M, Hausman D, Smyth MJ, Sivakumar PV. Interleukin 21: combination strategies for cancer therapy. Nat Rev Drug Discov 2008;7:231-40.
12. Andorsky DJ, Timmerman JM. Interleukin-21: biology and application to cancer therapy. Expert Opin Biol Ther 2008;8:1295-307.
13. Parrish-Novak J, Dillon SR, Nelson A, Hammond A, Sprecher C, Gross JA, et al. Interleukin21 andits receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 2000;408:57-63.
14. Strengell M, Matikainen S, Sirén J, Lehtonen A, Foster D, Julkunen I, et al. IL-21 in synergy with IL-15 or IL-18 enhances IFN-gamma production in human NK and T cells. J Immunol 2003;170:5464-9. (Pubitemid 36617833)
15. Moroz A, Eppolito C, Li Q, Tao J, Clegg CH, Shrikant PA. IL-21 enhances and sustains CD8+ T cell responses to achieve durable tumor immunity: comparative evaluation of IL-2, IL-15, and IL-21. J Immunol 2004;173:900-9. (Pubitemid 38924263)
16. Li Y, Bleakley M, Yee C. IL-21 influences the frequency, phenotype, and affinity of the antigen-specific CD8 T cell response. J Immunol 2005;175:2261-9. (Pubitemid 41113833)
17. Li Y, Yee C. IL-21 mediated Foxp3 suppression leads to enhanced generation of antigen-specific CD8+ cytotoxic T lymphocytes. Blood 2008;111:229-35.
18. Liu S, Lizée G, Lou Y, Liu C, Overwijk WW, Wang G, et al. IL-21 synergizes with IL-7 to augment expansion and anti-tumor function of cytotoxic T cells. Int Immunol 2007;19:1213-21. (Pubitemid 47500644)
19. Zeng R, Spolski R, Finkelstein SE, Oh S, Kovanen PE, Hinrichs CS, et al. Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function. J Exp Med 2005;201:139-48. (Pubitemid 40130091)
20. Sivori S, Cantoni C, Parolini S, Marcenaro E, Conte R, Moretta L, et al. IL-21 induces both rapid maturation of human CD34+ cell precursors towards NK cells and acquisition of surface killer Ig-like receptors. Eur J Immunol 2003;33:3439-47. (Pubitemid 37541122)
21. Skak K, Frederiksen KS, Lundsgaard D. Interleukin-21 activates human natural killer cells and modulates their surface receptor expression. Immunology 2008;123:575-83. (Pubitemid 351280971)
22. Coquet JM, Kyparissoudis K, Pellicci DG, Besra G, Berzins SP, Smyth MJ, et al. IL-21 is produced by NKT cells and modulates NKT cell activation and cytokine production. J Immunol 2007;178:2827-34. (Pubitemid 46333160)
23. Peluso I, Fantini MC, Fina D, Caruso R, Boirivant M, MacDonald TT, et al. IL-21 counteracts the regulatory T cell-mediated suppression of human CD4+ T lymphocytes. J Immunol 2007;178:732-9. (Pubitemid 46095145)
24. Gowda A, Ramanunni A, Cheney C, Rozewski D, Kindsvogel W, Lehman A, et al. Differential effects of IL-2 and IL-21 on expansion of the CD4+ CD25+ Foxp3+ T regulatory cells with redundant roles in natural killer cell mediated antibody dependent cellular cytotoxicity in chronic lymphocytic leukemia. MAbs 2010;2:35-41.
25. Konforte D, Simard N, Paige CJ. IL-21: an executor of B cell fate. J Immunol 2009;182:1781-7.
26. Brenne AT, Ro TB, Waage A, Sundan A, Borset M, Hjorth-Hansen H. Interleukin-21 is a growth and survival factor for human myeloma cells. Blood 2002;99:3756-62. (Pubitemid 34534548)
27. Ménoret E, Maïga S, Descamps G, Pellat-Deceunynck C, Fraslon C, Cappellano M, et al. IL-21 stimulates human myeloma cell growth through an autocrine IGF-1 loop. J Immunol 2008;181:6837-42.
28. Scheeren FA, Diehl SA, Smit LA, Beaumont T, Naspetti M, Bende RJ, et al. IL-21 is expressed in Hodgkin lymphoma and activates STAT5: evidence that activated STAT5 is required for Hodgkin lymphomagenesis. Blood 2008;111:4706-15.
29. Akamatsu N, Yamada Y, Hasegawa H, Makabe K, Asano R, Kumagai I, et al. High IL-21 receptor expression and apoptosis induction by IL-21 in follicular lymphoma. Cancer Lett 2007;256:196-206. (Pubitemid 47418346)
30. de Totero D, Capaia M, Fabbi M, Croce M, Meazza R, Cutrona G, et al. Heterogeneous expression and function of IL-21R and susceptibility to IL-21-mediated apoptosis in follicular lymphoma cells. Exp Hematol 2010;38:373-83.
31. de Totero D, Meazza R, Zupo S, Cutrona G, Matis S, Colombo M, et al. Interleukin-21 receptor (IL-21R) is up-regulated by CD40 triggering and mediates proapoptotic signals in chronic lymphocytic leukemia B cells. Blood 2006;107:3708-15.
32. Gowda A, Roda J, Hussain SR, Ramanunni A, Joshi T, Schmidt S, et al. IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro. Blood 2008;111:4723-30.
33. Jahrsdörfer B, Blackwell SE, Wooldridge JE, Huang J, Andreski MW, Jacobus LS, et al. B-chronic lymphocytic leukemia cells and other B cells can produce granzyme B and gain cytotoxic potential after interleukin-21-based activation. Blood 2006;108:2712-9.
34. Sarosiek KA,Malumbres R, Nechushtan H,Gentles AJ, Avisar E, Lossos IS. Novel IL-21 signaling pathway up-regulates c-Myc and induces apoptosis of diffuse large B-cell lymphomas. Blood 2010;115:570-80.
35. Kindsvogel W, Hughes SD, Bannink M, Heipel B, Johnson R, Sivkumar P, et al. IL-21 enhances rituximab-mediated killing of B-lymphoma cell lines in vitro and in vivo. J Clin Oncol 2004;22:Abstract 2581.
36. Hughes SD, Ponce RA, Krejsa C, Fringes W, Bartsch S, Hill JP, et al. IL-21 improves rituximab-mediated B cell depletion. Blood 2005; 106:345.
37. Davis ID, Brady B, Kefford RF, Millward M, Cebon J, Skrumsager BK, et al. Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trial. Clin Cancer Res 2009;15:2123-9.
38. Davis ID, Skrumsager BK, Cebon J, Nicholaou T, Barlow JW, Moller NP, et al. An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma. Clin Cancer Res 2007;13:3630-6. (Pubitemid 46955126)
39. Thompson JA, Curti BD, Redman BG, Bhatia S, Weber JS, Agarwala SS, et al. Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma. J Clin Oncol 2008; 26:2034-9.
40. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
41. Kahl BS, Bartlett NL, Leonard JP, Chen L, Ganjoo K, Williams ME, et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study. Cancer 2010;116:106-14.
42. Foran JM, Rohatiner AZ, Cunningham D, Popescu RA, Solal-Celigny P, Ghielmini M, et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantlecell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 2000;18:317-24. (Pubitemid 30056420)
43. McLaughlin P, Grillo-López AJ, Link BK, Levy R, Czuczman MS, Williams ME, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16: 2825-33. (Pubitemid 28363048)
44. Gelebart P, Zak Z, Anand M, Dien-Bard J, Amin HM, Lai R. Interleukin- 21 effectively induces apoptosis in mantle cell lymphoma through a STAT1-dependent mechanism. Leukemia 2009;23: 1836-46.